A few developments in the marijuana industry have kept shorts of cannabis stocks at bay, a new report from research firm S3 Analytics stated.

On Wednesday (November 20), the firm published a study indicating short sellers of the marijuana public market were down US$272 million during the trading session, for the top 20 cannabis stocks tracked by S3 Analytics.

The report noted that short exposure for cannabis is up 16 percent so far this year for a total of US$389 million.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“Short selling is fairly concentrated to a handful of names, with only six stocks topping US$100 million of short interest,” the report said. It was authored by Ihor Dusaniwsky, managing director of predictive analytics at S3 Partners — the parent firm of S3 Analytics.

The researcher identified that the short market has seen a year-long trend of net short selling for the top 20 cannabis names and has so far reached US$1.41 billion.

“The increased short selling was needed to maintain overall short exposure in the sector as sector-wide price weakness decreased the notional value of the total short positions by just over US$1 billion,” Dusaniwsky wrote.

According to the report, a combination of the positive vote for the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act) by the House Judiciary Committee helped cause the drop for shorts.

Alongside the vote, the following developments also caused the short dip:

  • Canopy Growth (NYSE:CGC,TSX:WEED) obtaining a rate raise from the wealth management division of Bank of America (NYSE:BAC);
  • Cronos Group (NASDAQ:CRON,TSX:CRON) investee Altria Group (NYSE:MO) upping its stake in the marijuana company to keep a 45 percent ownership of Cronos; and
  • The Green Organic Dutchman (TSX:TGOD,OTCQX:TGODF) announcing distribution for its products in Alberta, Manitoba and Nova Scotia.

Dusaniwsky said the top shorted stocks from the leading pack of 20 were Cronos, Canopy Growth and GW Pharma (NYSE:GWPH).

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less